Get the Stockscreener App
3.2415
2.49%
0.0815
Amylyx Pharmaceuticals Inc stock is traded at $3.2415, with a volume of 95,966.
It is up +2.49% in the last 24 hours and down -6.13% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
See More
Previous Close:
$3.16
Open:
$3.15
24h Volume:
95,966
Relative Volume:
0.12
Market Cap:
$270.78M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
4.6307
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
-1.86%
1M Performance:
-6.13%
6M Performance:
+54.96%
1Y Performance:
-83.45%
1-Day Range:
$3.105
$3.27
1-Week Range:
$2.865
$3.40
52-Week Range:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.245 | 270.78M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.93 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.56 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.50 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.64 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.56 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Top Executive Sells Thousands in Amylyx Pharmaceuticals Stock! - TipRanks
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery - Seeking Alpha
Q4 Earnings Preview: Can Amylyx Pharmaceuticals Deliver Strong 2024 Results? - StockTitan
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - The Bakersfield Californian
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to Join – Contact Levi & Korsinsky - accessnewswire.com
IMMINENT AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Levi & Korsinsky Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Amylyx Pharmaceuticals (AMLX) to Release Quarterly Earnings on Thursday - Defense World
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
FDA clears Amylyx to resume ALS drug trial in North America - MSN
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - MSN
AMLX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: A Comprehensive Overview and Future Outlook - EIN News
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Analysts - Armenian Reporter
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - Markets Insider
SG Americas Securities LLC Reduces Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - Markets Insider
There is no doubt that Amylyx Pharmaceuticals Inc (AMLX) ticks all the boxes. - SETE News
2025-02-13 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect | NDAQ:AMLX | Press Release - Stockhouse Publishing
AMLX 3-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action - ACCESS Newswire
abrdn plc Sells 249,437 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - Markets Insider
Analysts Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Amylyx Pharmaceuticals Inc (AMLX) presents a great opportunity, but the stock is slightly undervalued - US Post News
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation - Markets Insider
2025-02-10 | Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
Amylyx Pharmaceuticals Inc [AMLX] Stock sold by Insider Mazzariello Gina for $12839.0 - Knox Daily
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Bakersfield Californian
Amylyx (AMLX) Sets Stage for Major Strategic Updates at Premier Healthcare Conference - StockTitan
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 3,678 Shares - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Sells $41,122.97 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - Markets Insider
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $12,836.22 in Stock - Armenian Reporter
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - Markets Insider
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares - MSN
Taking on analysts’ expectations and winning: Amylyx Pharmaceuticals Inc (AMLX) - SETE News
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals’ co-CEO Justin Klee sells $41,103 in shares By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals Executives Cash In on Stock Sales - TipRanks
Research Analysts Set Expectations for AMLX FY2025 Earnings - MarketBeat
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Klee Justin B. | Co-Chief Executive Officer |
Feb 05 '25 |
Option Exercise |
1.57 |
36,310 |
57,007 |
3,201,243 |
| Mazzariello Gina | Chief Legal Officer |
Feb 03 '25 |
Sale |
3.49 |
3,678 |
12,839 |
139,090 |
| Cohen Joshua B | Co-Chief Executive Officer |
Feb 03 '25 |
Sale |
3.47 |
11,851 |
41,108 |
3,201,247 |
| Klee Justin B. | Co-Chief Executive Officer |
Feb 03 '25 |
Sale |
3.47 |
11,855 |
41,104 |
3,164,933 |
| Klee Justin B. | Co-Chief Executive Officer |
Jan 06 '25 |
Sale |
4.04 |
7,471 |
30,202 |
3,176,788 |
| Cohen Joshua B | Co-Chief Executive Officer |
Jan 06 '25 |
Sale |
4.05 |
7,471 |
30,232 |
3,213,098 |
| Bedrosian Camille L | Chief Medical Officer |
Dec 02 '24 |
Sale |
5.54 |
5,421 |
30,007 |
138,380 |
| Klee Justin B. | Co-Chief Executive Officer |
Nov 04 '24 |
Option Exercise |
1.57 |
63,690 |
99,993 |
3,184,259 |
| Klee Justin B. | Co-Chief Executive Officer |
Sep 30 '24 |
Sale |
3.20 |
18,589 |
59,429 |
3,120,569 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 30 '24 |
Sale |
3.20 |
18,589 |
59,414 |
3,220,569 |
1.77%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):